Bio-FD&C Co. Ltd.
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, skin texture, anti-inflammation/skin soot… Read more
Bio-FD&C Co. Ltd. (251120) - Net Assets
Latest net assets as of September 2025: ₩68.46 Billion KRW
Based on the latest financial reports, Bio-FD&C Co. Ltd. (251120) has net assets worth ₩68.46 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩72.27 Billion) and total liabilities (₩3.80 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩68.46 Billion |
| % of Total Assets | 94.74% |
| Annual Growth Rate | 42.93% |
| 5-Year Change | 408.11% |
| 10-Year Change | N/A |
| Growth Volatility | 79.73 |
Bio-FD&C Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Bio-FD&C Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bio-FD&C Co. Ltd. (2018–2024)
The table below shows the annual net assets of Bio-FD&C Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩63.13 Billion | +7.70% |
| 2023-12-31 | ₩58.62 Billion | +10.65% |
| 2022-12-31 | ₩52.98 Billion | +233.55% |
| 2021-12-31 | ₩15.88 Billion | +27.83% |
| 2020-12-31 | ₩12.42 Billion | +24.71% |
| 2019-12-31 | ₩9.96 Billion | +34.61% |
| 2018-12-31 | ₩7.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-FD&C Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 602.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩26.07 Billion | 41.29% |
| Common Stock | ₩4.35 Billion | 6.89% |
| Other Components | ₩32.72 Billion | 51.83% |
| Total Equity | ₩63.13 Billion | 100.00% |
Bio-FD&C Co. Ltd. Competitors by Market Cap
The table below lists competitors of Bio-FD&C Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
$48.22 Million |
|
Citizens Bancshares Corp
PINK:CZBS
|
$48.22 Million |
|
Carnaby Resources Ltd
AU:CNB
|
$48.22 Million |
|
PADAUK Technology Co. Ltd
TWO:6716
|
$48.23 Million |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
$48.20 Million |
|
Leo Lithium Limited
PINK:LLLAF
|
$48.19 Million |
|
Plastron Precision Co Ltd
TWO:6185
|
$48.19 Million |
|
Ramayana Lestari Sentosa Tbk
JK:RALS
|
$48.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-FD&C Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 58,616,934,670 to 63,131,417,990, a change of 4,514,483,320 (7.7%).
- Net income of 4,500,920,350 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.50 Billion | +7.13% |
| Other Changes | ₩13.56 Million | +0.02% |
| Total Change | ₩- | 7.70% |
Book Value vs Market Value Analysis
This analysis compares Bio-FD&C Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.31x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩851.16 | ₩13880.00 | x |
| 2019-12-31 | ₩1145.77 | ₩13880.00 | x |
| 2020-12-31 | ₩1428.83 | ₩13880.00 | x |
| 2021-12-31 | ₩2147.57 | ₩13880.00 | x |
| 2022-12-31 | ₩6211.48 | ₩13880.00 | x |
| 2023-12-31 | ₩6872.70 | ₩13880.00 | x |
| 2024-12-31 | ₩7402.02 | ₩13880.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-FD&C Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.13%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.01%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.07x
- Recent ROE (7.13%) is below the historical average (13.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 5.46% | 6.73% | 0.48x | 1.68x | ₩-336.25 Million |
| 2019 | 25.71% | 30.22% | 0.55x | 1.53x | ₩1.57 Billion |
| 2020 | 19.81% | 28.49% | 0.49x | 1.42x | ₩1.22 Billion |
| 2021 | 18.31% | 24.29% | 0.52x | 1.45x | ₩1.32 Billion |
| 2022 | 8.18% | 27.34% | 0.27x | 1.11x | ₩-962.47 Million |
| 2023 | 9.53% | 35.82% | 0.25x | 1.07x | ₩-276.54 Million |
| 2024 | 7.13% | 28.01% | 0.24x | 1.07x | ₩-1.81 Billion |
Industry Comparison
This section compares Bio-FD&C Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-FD&C Co. Ltd. (251120) | ₩68.46 Billion | 5.46% | 0.06x | $48.22 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |